The game is afoot in the obesity space as GLP-1 rivals Eli Lilly and Novo Nordisk take their showdown to a new level. Lilly ...

London: The World Health Organization (WHO) is set to officially back the use of weight-loss drugs as a treatment for obesity ...

Plainsboro, New Jersey Monday, May 5, 2025, 14:00 Hrs [IST] ...

You’ve probably been there — staring at another diet plan, another gym ad, another promise of results. And if you’ve ever ...

Our writer explains why he just added to a big loser to his Stocks and Shares ISA portfolio, despite it going against one of ...

On Friday, the company’s health services unit Evernorth unveiled new programs in a reliable growth area: helping payers ...

Merck KGaA to buy Springworks for $3.9 billion Merck KGaA (OTCPK:MKGAF) is set to acquire SpringWorks Therapeutics (SWTX) for ...

Gold edged higher in Asia amid losses in U.S. stock-index futures. The precious metal's direction is likely to be determined by equities' direction and risk appetite, said Fawad Razaqzada, a market ...

This report covers recent developments in the health sector, including proposed US federal budget cuts affecting scientific ...

which has a long list of candidates in clinical trials trying to chase down the current crop of injectables led by Novo Nordisk’s Wegovy (semaglutide) and Lilly’s Zepbound (tirzepatide).

But, he added, "we should not have tariffs." Novo Nordisk launched access to its popular weight loss GLP-1 drug, Wegovy, through multiple telehealth platforms, including Hims & Hers. Healthcare ...